Urate in Atherosclerotic Plaques Boosts Risk for CV Events

METHODOLOGY:

Traditional risk factors do not explain the higher risk for CV events in patients with gout and hyperuricemia; therefore, understanding the association between MSU deposits, frequently present in these conditions, and MACE may help identify patients at higher risk.
This retrospective cohort study included 189 patients (median age, 68 years) for a median follow-up time of 33 months: 131 with gout, 40 with hyperuricemia, and 18 control individuals who underwent dual-energy CT (DECT) of the affected limb and thorax.
DECT scans and coronary calcium scores were used to identify MSU deposits in CV plaques.

Overall, 85 patients (45%) exhibited CV MSU deposits, including 62 patients with gout, 22 with hyperuricemia, and one control individual.
Patients with CV MSU deposits had significantly higher cardiac disease marker levels, including C-reactive protein levels (median, 17.1 vs 5.6 mg/L; P = .007), uric acid levels (mean, 7.4 vs 6.4 mg/dL; P = .007), and calcium scores (median, 469.5 vs 5.35; P < .001), than those without the deposits.
MACE occurred in 35 patients and were more frequent in patients with CV MSU deposits (25.9%) than in those without (12.5%; odds ratio, 2.4; P = .018).
MACE incidence was significantly higher in patients with MSU deposits (31.8 vs 6.7 cases per 1000 patient-years).

Non-cardiac birth defects and long-term risk of cardiovascular hospitalisation Patients with heart defects are at risk of developing cardiovascular disease. Our objective was to determine if non-cardiac birth defects are associated with the risk of cardiovascular hospitalisation.

Urate in Atherosclerotic Plaques Boosts Risk for CV Events Patients with gout and hyperuricemia harboring cardiovascular (CV) monosodium urate (MSU) deposits in atherosclerotic plaques are at an increased risk for major adverse cardiovascular events (MACE).

Don't Overlook Underlying CV Risks In RA Treatmen Patients with rheumatoid arthritis (RA) carry a high risk for cardiovascular events, but mounting clinical evidence suggests they're being undertreated to manage that risk. Rheumatologists should consider a patient with RA's cardiovascular disease (CVD) status before deciding on RA treatments, a researcher of cardiometabolic disorders advised.

Microvascular disease and arrhythmias: a renewed focus on the myocardial microvasculature? Arrhythmias, and in particular atrial fibrillation (AF), are one of the greatest healthcare challenges of our time. Hospitalisation due to this condition is exponentially growing, and now outnumbers those for both heart failure and myocardial infarction.

In Angina, Gene Therapy Coaxes Heart Vessel Growth An experimental new gene therapy has specialists questioning whether heart vessel growth to restore blood flow could actually be possible in refractory angina after bypass surgery.